Overview

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

Status:
Completed
Trial end date:
2018-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vedolizumab